NOVOS is a science-first longevity biotechnology company founded in 2018 to address aging at its biological root. Rather than chasing wellness trends or isolated ingredients, NOVOS develops integrated longevity systems designed around the core mechanisms and hallmarks of aging.
Every formulation is built using a biology-first framework and validated through mechanistic studies, preclinical research, and human clinical trials. NOVOS collaborates with world-renowned scientists and research institutions, holds patents on multi-ingredient longevity systems, and conducts independent testing for purity and safety.
As a Public Benefit Corporation, NOVOS is legally committed to advancing human health and longevity alongside commercial success. Beyond products, the company actively supports longevity research, public education, and nonprofit initiatives accelerating the science of healthy aging.
To extend healthspan and longevity by treating aging as a measurable, targetable biological process—delivering rigorously validated, science-driven systems that protect long-term health before decline begins.
